Datawars: Grid Computing Democratizes Proteomics

Erica P. Johnson The young field of proteomics has quickly risen to match physics and meteorology in its huge appetite for computational capacity. According to Sylvie Langevin, development group manager of Montreal-based proteomics firm Caprion Pharmaceuticals, the computer processing and data handling requirements of proteomics exceed those of genomics by a factor approaching one million. "In genomics we have files of several kilobytes in size, but in proteomics we're closer to 1 [gigabyte],"

Written byPhillip Hunter
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

The young field of proteomics has quickly risen to match physics and meteorology in its huge appetite for computational capacity. According to Sylvie Langevin, development group manager of Montreal-based proteomics firm Caprion Pharmaceuticals, the computer processing and data handling requirements of proteomics exceed those of genomics by a factor approaching one million. "In genomics we have files of several kilobytes in size, but in proteomics we're closer to 1 [gigabyte]," Langevin says.

Fortunately proteomics problems, such as three-dimensional visualization of protein structures and searching for matching sequences, can readily be broken up into small components that can be processed separately on different computers and then reassembled at the end. "In the trade we call them 'embarrassingly parallel,'" says Brian Carter, head of life science solutions for IBM in the United Kingdom.

GRID LINES This makes proteomics ripe for grid computing, the fast-emerging computational model for sharing resources such as servers ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies